In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MediciNova gets rights to Kissei's premature labor compound

Executive Summary

MediciNova (premature labor, cancer, and asthma therapeutics) has licensed exclusive worldwide rights (excluding Japan) to Kissei Pharmaceutical's KUR-1246, a drug candidate to begin US Phase I studies for premature labor. MediciNova will be developing the compound as MN-221.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies